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Abstract
Extensive scientific efforts are directed towards finding new and improved platinum anticancer agents. A promising
approach is the encapsulation of cisplatin in sterically stabilized, long circulating, PEGylated 100 nm liposomes. This
liposomal cisplatin (STEALTH cisplatin, formerly known as SPI-77) shows excellent stability in plasma and has a longer
circulation time, greater efficacy and lower toxicity than much free cisplatin. However, so far, the physicochemical
characterization of STEALTH cisplatin has been limited to size distribution, drug-to-lipid ratio and stability. Information on
the physical state of the drug in the liposome aqueous phases and the drug’s interaction with the liposome membrane has
been lacking. This study was aimed at filling this gap. We report a multinuclear NMR study in which several techniques have
been used to assess the physical nature of cisplatin in liposomal formulations and if and to what extent the drug affects the
liposome phospholipids. Since NMR detects only the soluble cisplatin in the liposomes and not the insoluble drug, combining
NMR and atomic absorption data enables one to determine how much of the encapsulated drug is soluble in the
intraliposomal aqueous phase. Our results indicate that almost all of the cisplatin remains intact during the loading process,
and that the entire liposomal drug is present in a soluble form in the internal aqueous phase of the liposomes. ß 2001
Elsevier Science B.V. All rights reserved.
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1. Introduction
Since it was ¢rst discovered by Rosenberg et al. [1],
cisplatin (cis-diamminedichloroplatinum(II), cis-
DDP) has become one of the most widely used anti-
cancer drugs in treating a variety of solid tumors,
including testicular, head and neck, and lung tumors
[2]. The cellular target of the drug is the DNA, with
which it forms stable adducts that are responsible for
the drug’s anticancer activity [3].
The drug enters cells by passive di¡usion. The low-
er intracellular chloride ion concentration (4 mM vs.
103 mM in the plasma) enables the drug to exchange
its ¢rst chloride ligand with a water molecule, thus
forming the positively charged mono-aqua species
that can form covalent monofunctional adducts
with the DNA (see Fig. 1). The monofunctional ad-
duct reacts further, by substitution of its chloride
ligand, to form bifunctional cross-links [4]. The ma-
jor adduct formed between cisplatin and DNA is the
bidentate, 1,2-intrastrand cross-link, cis-Pt-GG, in
which cis-[Pt(NH3)2]2 binds two adjacent guanine
N7 atoms (Fig. 1). Nuclear magnetic resonance and
crystallographic studies show that the adduct forma-
tion unwinds the DNA by about 321‡ and causes a
kink of V40^58‡ in the duplex towards the major
groove, and widens the minor groove of the plati-
nated duplex at the lesion site [5,6]. These structural
modi¢cations may be the recognition motifs for high
mobility group domains, such as HMG1, Ixr1 and
hUBF, which bind cis-platinated DNA [7,8]. Once
bound by these cellular proteins, the intrastrand
cross-links are shielded from cellular repair mecha-
nisms, resulting in cancer cells becoming more sensi-
tive to the drug.
Platinum anticancer drugs are administered by in-
travenous injection, and within 1 day, 65^98% of the
platinum in the blood plasma is protein bound [9,10].
The binding of cisplatin to proteins reduces the uri-
nary excretion of platinum and causes the deposition
of platinum in tissues. In addition, the binding of
cisplatin to proteins and enzymes is believed to be
the cause of many of the severe side e¡ects exhibited
by the drug, especially ototoxicity and nephrotoxicity
[11,12]. So far, attempts to prevent neuro- and neph-
rotoxicity have failed.
Cisplatin has additional drawbacks, such as low
solubility in aqueous solutions (7 mM, 2.10 mg/ml
at 37‡C), severe toxicity (i.e., nephrotoxicity, myelo-
suppression, central nervous system impairment) and
side e¡ects such as nausea and vomiting [13]. Ac-
quired multi-drug resistance is known to develop in
patients receiving cisplatin chemotherapy.
Although extensive e¡orts were devoted to over-
coming these major issues by development of new
generations of platinum derivatives which are less
toxic and more active than cisplatin and/or do not
display cross-resistance, the improvements were min-
imal [14]. An alternative approach is the encapsula-
tion of cisplatin in sterically stabilized 100 nm lipo-
somes, based on the promising animal and clinical
data obtained from Doxil (a STEALTH liposomal
formulation of doxorubicin HCl; ALZA Corpora-
tion, Mountain View, CA) loaded in the aqueous
phase of sterically stabilized 100 nm liposomes
[15,16]. Toxicity, pharmacokinetics, tissue distribu-
tion and therapeutic e⁄cacy of cisplatin encapsulated
in long circulating PEGylated liposomes were re-
cently described [17,18]. As expected, STEALTH cis-
platin has excellent stability in plasma, a much lon-
ger circulation time, better e⁄cacy and lower toxicity
than free cisplatin. However, the characterization of
STEALTH cisplatin has been limited to size distri-
bution, drug-to-lipid ratio, and stability. The physi-
cal and chemical characteristics of the drug in the
liposome’s aqueous phase and the drug’s interaction
with the liposome membrane have not been reported.
NMR is one of the most powerful tools for eval-
uation of liposomal formulations since the aniso-
tropic nature of molecular motion within the lipid
bilayers and the anisotropy of the membrane struc-
ture can be evaluated by this technique [19,20]. One
of the major advantages of NMR applications is that
the method is based on the use of intrinsic reporter
moieties (the various nuclei, i.e., 13C, 31P, 1H, 15N,
195Pt). Most other approaches, such as £uorescent
techniques and electron spin resonance (ESR), re-
quire the use of bulky external probe moieties. In
the case of cisplatin-loaded liposomes, NMR pro-
vides important information both on the liposome
Fig. 1. Cisplatin-DNA adducts.
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phospholipids (physical state, rate of motion) and on
the platinum complex (oxidation state and coordina-
tion sphere). The combination of NMR and atomic
absorption spectroscopy (AAS) can be used to quan-
tify the amount of soluble platinum in the liposome
formulations.
We report a multinuclear NMR study in which
several techniques were used to assess (a) the physical
and chemical nature of cisplatin in liposomal formu-
lations and (b) the extent to which the drug a¡ects
liposome phospholipids.
2. Experimental procedures
2.1. Preparation and characterization of 15N-labeled
cisplatin (cis-Pt(15NH3)2Cl2)
cis-15N-Diamminedichloroplatinum(II) (cisplatin)
was synthesized according to the procedure described
by Boreham et al. [19]. The product was character-
ized by both 195Pt NMR spectroscopy and by the
thiourea test. Thiourea was added to an aqueous so-
lution of the 15N-labeled cisplatin, and the solution
was heated to 40^50‡C. The appearance of a yellow
color is indicative that the product is in the cis con-
¢guration, whereas the appearance of a colorless so-
lution indicates the presence of the trans isomer.
The cis-15N-DDP was dissolved in dimethylform-
amide (DMF) and analyzed by 195Pt NMR.
2.2. Preparation of liposomes containing cisplatin
2.2.1. Preparation of 15N-cisplatin encapsulated in
sterically stabilized liposomes (STEALTH
cisplatin)
15N-Cisplatin (8.5 mg/ml) was dissolved in 0.9%
NaCl at 65‡C and left at this temperature for 1 h.
Lipids (HSPC/cholesterol/2000PEG-DSPE 51:44:5)
were dissolved in ethanol. The lipids were hydrated
by adding this ethanolic solution to the drug mix-
ture. Final lipid concentration was 150 mg/ml
(15%) in 10% ethanol, at 65‡C. The mixture was
kept stirring for 1 h at 65‡C, then extruded at
65‡C, 11 times through 200 nm pore size polycarbon-
ate ¢lters using the LiposoFast syringe extruder
(Avestin, Ottawa, ON, Canada), followed by extru-
sion through a 100 nm pore size polycarbonate ¢lter.
Sized liposomes (V100 nm) were allowed to cool to
room temperature (RT). During the cooling, a heavy
yellow precipitate formed. The supernatant was col-
lected and allowed more standing time at room tem-
perature. More precipitation occurred, and the
supernatant was collected again. The sample was di-
luted twofold and dialyzed against 10% sucrose con-
taining 1 mM NaCl, and 5 times against 100 vols. of
10% sucrose containing 1 mM NaCl at room temper-
ature. Under these conditions, a complete equilibra-
tion with 10% sucrose containing 1 mM NaCl should
occur. Finally, histidine bu¡er (pH 6.5) was added to
a ¢nal concentration of 10 mM. The ¢nal liposome
dispersion was a translucent white. Aliquots of the
liposomes and of both precipitates were analyzed by
heteronuclear single quantum coherence (HSQC) at
30‡C.
2.2.2. Preparation of cisplatin encapsulated in
sterically stabilized liposomes (STEALTH
cisplatin)
STEALTH cisplatin liposomes (V100 nm) were
prepared as described in Section 2.2.1 (except that
commercial cisplatin was used). Sample 4 (Table 1)
was frozen once and then thawed; both the cisplatin
and the liposomes remained intact. Large unilamellar
liposomes were prepared containing 99 mg/ml total
lipids and 1.64 mg/ml Pt.
2.3. Liposome characterization: analysis of liposome
concentration, size and integrity
Liposomes were characterized for their size distri-
bution using photon correlation spectroscopy [20].
Phospholipid concentration was characterized using
a modi¢ed Bartlett procedure [20]. Lipid degradation
was determined using TLC [20,21] and the increase
in levels of non-esteri¢ed fatty acids [21].
2.4. NMR measurements
2.4.1. 195Pt NMR
195Pt NMR measurements were carried out on a
Varian VXR-300S spectrometer having a 7.05 T
magnet equipped with a 5 mm computer-switchable
probe. The platinum chemical shifts were measured
relative to the external reference signal of K2PtCl4,
set at 31624 ppm. Data were collected with and
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without broad-band decoupling of the protons, using
a spectral width of 100.0 kHz and acquisition time of
0.010 s. Usually, 350 000 pulses or more were ac-
quired and a line broadening of 300 Hz was applied.
The samples were measured, without spinning, at
37‡C and 60‡C. A capillary containing 2 mg/ml
(4.82 mM) K2PtCl4 was added to the NMR tubes
as an internal reference of a known concentration.
The data were apodized using a line broadening
equal to the natural line width (in Hz) prior to pro-
cessing and integration.
2.4.2. 31P NMR
31P measurements were carried out at room tem-
perature and at 60‡C using a 5 mm computer-switch-
able probe. The 31P chemical shifts were measured
relative to phosphoric acid set at 0 ppm. Data were
collected with broad-band decoupling of the protons,
using a spectral width of 10 000 Hz, and an acquisi-
tion time of 1.6 s. Usually, 250 pulses or more were
acquired and a line broadening of 20.0 Hz was ap-
plied. Placebo (control) and cisplatin-loaded lipo-
somes were studied by 31P NMR. The large (V100
nm) unilamellar vesicles (LUV) were composed of
hydrogenated phosphatidylcholine (HPC), cholester-
ol and 2000PEG-DSPE at a mole ratio of 55:40:5.
Samples were prepared by mixing 700 Wl of the orig-
inal liposome sample with 70 Wl of 2H2O.
2.4.3. HSQC NMR measurements
All [1H, 15N] HSQC data were obtained using a
Bruker DXR 400 MHz NMR spectrometer,
equipped with a 5 mm multinuclear inverse detection
probe. The 2D data were recorded using the Bruker
sequence of INVIGSTP (inverse detection 2D 1H-X
correlation via double INEPT transfer, phase sensi-
tive using TPPI with decoupling during acquisition).
15N spins were irradiated during the acquisition
time using the GARP-1 sequence. The 15N chemical
shifts were externally referenced to 1.5 M NH4Cl in
1 M HCl (NN = 0 ppm, NH = 7 ppm); 1H chemical
shifts were externally referenced to TSP (Me3Si-
(CD2)2CO2Na) (NH = 0 ppm). Two to eight transients
were acquired, using an acquisition time of 0.251 s,
spectral widths of 2 kHz in both f2 and f1 dimen-
sions, and 256 increments of t1. All spectra were
acquired at 300 K (27‡C). Spectra were collected in
V20 min. The data were processed using Bruker
software, with no line broadening.
2.4.3.1. Sample preparation for HSQC experi-
ments. The 15N-cisplatin (8.5 mg/ml) was dissolved
either in 0.9% NaCl or in 10% sucrose, at 65‡C.
Control samples, without lipids, were prepared and
processed according to the same procedures de-
scribed above for STEALTH cisplatin preparation
(see Section 2.2.1). After cooling, histidine bu¡er
(10 mM, pH 6.5) was added. Treated samples were
stored at 4‡C or 320‡C.
2.4.4. Quanti¢cation of platinum content by
195Pt NMR
K2PtCl4 was chosen as an internal reference since
it is a stable compound whose chemical shift (31624
ppm) is in close proximity to that of cisplatin (32100
ppm), yet is distant enough to avoid overlapping.
The K2PtCl4 (2 mg/ml, 4.82 mM), was sealed in a
glass capillary, and concentrated HCl was added to
prevent its hydrolysis. The capillary was inserted into
the 5 mm NMR tube containing the sample, and the
Table 1
Liposomal formulations used for 195Pt NMR spectroscopy
Parameter Sample 1 Sample 2 Sample 3 Sample 4
Size (nm) 112 125 100 107
cis-DDP (mg/ml) 1.0 1.0 0.9 0.9
Lipid (mM) 104 89 110 110
Linewidth (Hz, 37‡C) 848.08 844.51 789.40 797.53
Linewidth (Hz, 60‡C) 994.08 1017.44 861.06 868.92
External phase 10% sucrose 0.9% NaCl 3% sucrose 3% sucrose
1 mM NaCl 3.3% NaCl 3.3% NaCl
10 mM histidine 10 mM histidine 10 mM histidine 10 mM histidine
pH 6.5 pH 6.5 pH 6.5 pH 6.5
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195Pt NMR spectrum was acquired as described
above.
To test the method’s accuracy, three cisplatin
samples of varying concentrations (1.54, 2.0 and
2.31 mg/ml) were measured in the presence of the
capillary at 37‡C. The areas under the curves were
integrated relative to the area under the reference
peak, and the elemental platinum concentration
was calculated. To verify the calculated concentra-
tions, AAS was performed.
2.5. Atomic absorption spectroscopy
Atomic absorption measurements were performed
on a Varian SpectrAA Zeeman 300 spectrometer.
The platinum concentration was calculated according
to a calibration curve of a known concentration of a
K2PtCl4 stock solution (250 ng/ml, 6.02U1034 mM).
3. Results
3.1. Analysis by 195Pt NMR
3.1.1. 195Pt NMR of 15N-labeled cisplatin
cis-Pt(15NH3)2Cl2 was prepared (see Section 2.1)
and characterized by 195Pt NMR spectroscopy. The
broad-band decoupled spectrum shows the expected
triplet due to the coupling of two equivalent 15N
atoms (Fig. 2a). When the broad-band decoupling
was turned o¡, each of the three 195Pt resonances
was split to a septet by the six equivalent hydrogens
(Fig. 2b).
3.1.2. 195Pt NMR of cisplatin encapsulated in
liposomes
195Pt NMR measurements of liposome-encapsu-
lated cisplatin clearly show a single chemical shift
(range 31350 to 32700 ppm) at 32139.7 ppm, in-
dicating mainly (s 90%) one species of Pt(II), which
is the intact cisplatin (Fig. 3). No additional plati-
num peaks were detected, indicating that no other
platinum species (i.e., platinum tri- or tetra-amine)
were formed, though adducts of Pt(II) with large
molecules would not be observed by 195Pt NMR.
Fig. 2. 195Pt NMR spectra of cis-Pt(15NH3)2Cl2 (a) with and
(b) without broad-band decoupling.
Fig. 3. 195Pt NMR spectrum of cisplatin encapsulated in lipo-
somes.
Fig. 4. 31P NMR spectra of (a) cisplatin-containing liposomes
and (b) control liposomes.
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Pt(II) can undergo a two-electron disproportionation
to give solid Pt(0) and soluble Pt(IV) complexes, es-
pecially when they are heated in non-acidic solutions.
No black precipitate was detected in the samples,
suggesting that no Pt(0) was present, and no peaks
were observed in the 195Pt NMR in the region be-
tween +1000 and 3500 ppm, indicating that no
Pt(IV) complexes were present in the liposomal dis-
persion.
3.2. Analysis by 31P NMR
The 31P NMR spectra of the liposome formula-
tions described in Table 2 were measured; they dis-
played the slightly asymmetric peaks typical of phos-
pholipid vesicles. The same samples were measured
by 195Pt NMR to verify their platinum content. At
room temperature, the 31P peak observed was very
broad. This is in agreement with previous data of
vesicles composed of saturated phospholipids and
cholesterol in their liquid ordered phase, below the
gel-to-liquid crystalline phase transition temperature
(Tm) of the matrix lipids (Tm = 52.5‡C for HPC) [22].
At 60‡C (above Tm for HPC), sharp spectra were
obtained for both the control and platinum-contain-
ing liposomes. At 60‡C, V10 scans were su⁄cient to
produce reliable data with high signal-to-noise ratio
(Fig. 4). Peak analysis revealed somewhat asymmet-
ric peaks for both (skewness to the right), as is ex-
pected for phospholipid vesicles. Measurement of the
linewidths at half the height can serve as a criterion
for the interaction of the platinum with the phospho-
lipids in the formulation. Linewidths at half the
height (vX1=2) were determined at 60‡C, and values
of 6.3 ppm and 4.2 ppm were obtained for the con-
trol and the cisplatin liposomes, respectively.
Fig. 5. HSQC spectrum of cis-Pt(15NH3)2Cl2 in water (a), and (b) an enlargement of region I. (c) Schematic representation of the spe-
cies detected in the HSQC spectrum of 15N-labeled cisplatin.
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3.3. Analysis by HSQC
In a typical HSQC experiment we were able to
observe micromolar concentrations of cisplatin in
V20 min. In addition to the tremendous gain in
sensitivity, HSQC selectively detects only the protons
that are coupled to the 15N, thus ignoring all the
other protons in the solution (from the liposomes)
and simplifying the interpretation of the data. For
an overview of 1H-15N-HSQC NMR, see Section 4.2.
3.3.1. HSQC of 15N-labeled cisplatin in water
The HSQC of cis-Pt(15NH3)2Cl2 in water is de-
picted in Fig. 5. The correlation peaks are located
in region I, which is characteristic of Pt(II) com-
plexes. There are no peaks in region II, where the
Pt(IV) peaks are expected. An enlargement of region
I (Fig. 5b) shows that there are three peaks (A, B and
C) and each peak has additional satellites (A1P, A1Q,
A2P and A2Q). The satellites result from the spin-spin
coupling between the 195Pt (33% natural abundance)
and the protons/15N [23]. Peak A belongs to cis-
Pt(15NH3)2Cl2, where the two equivalent nitrogens
give rise to a single peak. Peaks B and C belong to
a single complex of cis-[Pt(15NH3)2Cl(H2O)], where
peak B is ascribed to the nitrogen that is trans to the
aqua ligand, and peak C to the nitrogen that is trans
to the chloride ligand (Fig. 5c). The 195Pt-15N cou-
pling constants can be measured from the distance
between A1P and A1Q, and the 195Pt-1H coupling
constants can be measured from the distance between
A1Q and A2Q. The hydrolysis reaction of cisplatin in
aqueous solutions is not easily observed by 195Pt
NMR, but is easily observed by HSQC. The results
obtained here are consistent with those reported in
the literature [23] (J(1H-195Pt) V64 Hz, J(15N-195Pt)
V320 Hz).
3.3.2. HSQC of 15N-labeled cisplatin encapsulated in
liposomes
HSQC spectra of cis-Pt(15NH3)2Cl2 passively en-
capsulated in the aqueous phase of V100 nm LUV
appear almost identical to the spectrum of the free
drug. Bu¡ers, such as histidine, were added after the
encapsulation was complete, and all excess drug was
removed. However, there is one small di¡erence be-
tween the spectral details of the HSQC of the 15N-
labeled cisplatin in water and in the liposomes: the
distance between the satellite peaks in the 15N lipo-
somal cisplatin is somewhat smaller than in the non-
encapsulated compound. The spectrum does not dis-
Fig. 6. HSQC spectrum of cis-Pt(15NH3)2Cl2 encapsulated in
the liposomes; the peak denoted as ‘X’ is unidenti¢ed.
Fig. 7. HSQC spectrum of cis-Pt(15NH3)2Cl2 following encapsu-
lation in the presence of a histidine bu¡er; peaks 1^7 are attrib-
uted to cis-Pt(15NH3)2Cl2-histidine species.
Fig. 8. HSQC spectrum of cisplatin following incubation with
N-acetylhistidine.
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play any peaks in the Pt(IV) region, indicating that
the process of encapsulation of cis-Pt(15NH3)2Cl2
into the liposomes did not cause disproportionation
of the cisplatin (Fig. 6). In addition, the lack of a
15NH4 peak in the spectrum suggests that no deam-
ination (loss of the 15N ligand) occurred and that all
the Pt(II) complexes can be accounted for by the
HSQC experiment. Visible in the spectrum are the
expected cisplatin peaks, as well as an unidenti¢ed
peak (marked X); HPLC chromatograms of these
samples detected only very minor impurities (6 5%)
(results not shown).
3.3.3. HSQC of 15N-labeled cisplatin encapsulated in
liposomes in the presence of a histidine bu¡er
The 1H-15N-HSQC spectra revealed peaks addi-
tional to those of the 15N-labeled compound after
exposing the 15N-labeled drug to histidine (Fig. 7).
Further experiments in which the 15N-cisplatin was
exposed to known quantities of histidine during lipo-
some preparation indicated that these foreign peaks
could be attributed to binding of the drug to the
histidine in the bu¡er during the encapsulation pro-
cess. We chose to test the reactivity of the 15N-la-
beled cisplatin towards biological bu¡ers. Protected
N-acetylhistidine was used in order to eliminate the
contribution of the histidine amino group. Following
24 h incubation of a 1:1 mole ratio of 15N-cisplatin
and N-acetylhistidine, various new peaks appeared,
probably belonging to cisplatin-histidine species (Fig.
8). These results were further veri¢ed by means of
HPLC; the chromatograms obtained indeed veri¢ed
the presence of a cisplatin-histidine species (V20^
30% of the platinum detected) (results not shown).
No additional peaks were detected when the 15N-cis-
platin was loaded into the liposomes in the absence
of histidine or when histidine was added after the
unencapsulated drug was removed (see Section
2.2.1). Similar results were obtained when N-BOC-
methionine was incubated for 24 h in the presence of
15N-cisplatin, at a 1:1 mole ratio.
3.4. Solubility studies
3.4.1. Visual precipitation studies
Visual assessment showed that the solubility
of cisplatin is temperature dependent. At 4‡C,
1 mg/ml cisplatin was completely soluble; at 37‡C,
2 mg/ml; at 65‡C, 8 mg/ml. No yellow precipitation
of cisplatin was detected in any of these cases.
3.4.2. Solubility studies in the aqueous phase and in
the presence of ethanol
We compared the solubility of cisplatin at 1 and
8 mg/ml at room temperature and at 65‡C (which are
the relevant temperatures for encapsulation of the
Table 2
Liposomal formulations used for 31P and 195Pt NMR spectroscopy
P (mg/ml) Phospholipids (mM) Total lipids (mg/ml) Pt (mg/ml) Sizea (nm) vX1=2 (60‡C) (ppm)
Control-SSL 2.65 86 109 ^ 104 6.3
Cisplatin-SSL 9.75 315 403 1.8 116 4.2
aAll size distributions were unimodal, S.D. did not exceed 15%.
Table 3
Quanti¢cation of cisplatin content by NMR and AAS
Weighed cis-DDP (mg/ml) cis-DDP calculated by AA (mg/ml) cis-DDP calculated by NMR (mg/ml)
18‡C 37‡C
1.5 1.5 1.4 1.4
2.0 2.0 1.8 1.8
2.3 2.3 2.1 2.1
5.1a 3.7b 2.1 3.2
aAt 60‡C, all 5.1 mg/ml cis-DDP could be quanti¢ed by 195Pt NMR.
bOnly 3.7 mg/ml of cis-DDP is accounted for, since some precipitation occurs during the AA measurement, carried out at room tem-
perature.
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drug in liposomes) in 0.9% NaCl and in 20% ethanol
in 0.9% NaCl. At 1 mg/ml, cisplatin was soluble
under all conditions. At 8 mg/ml, most of the cispla-
tin precipitated at room temperature, but most was
soluble at 65‡C. Heating, followed by a decrease to
room temperature, led to the precipitation of most of
the 8 mg/ml of the cisplatin which was dissolved at
65‡C, in both the absence and presence of 20% etha-
nol.
3.5. Quanti¢cation of cisplatin content by 195Pt NMR
The level of cisplatin in di¡erent liposome prepa-
rations was quanti¢ed using 195Pt NMR spectrosco-
py and AAS. The platinum content measured by
NMR was veri¢ed by AAS (Table 1).
3.6. E¡ect of 2000PEG on solubility and linewidth of
cisplatin as measured by 195Pt NMR
3.6.1. E¡ect of 2000PEG on solubility of cisplatin
The experiment was carried out at room temper-
ature to isolate the e¡ect of the 2000PEG and exclude
the contribution of a rise in temperature. Solubility
was studied using both visual precipitation and 195Pt
NMR measurements (see Sections 3.4 and 2.4.1).
Cisplatin, 5 mg/ml, was dissolved in the presence of
increasing concentrations of 2000PEG (10%, 20% and
40% 2000PEG). In the presence of 40% 2000PEG, sol-
ubility was achieved fastest. Ten percent 2000PEG
had almost no e¡ect on the solubility at RT, as the
integrated peak observed was equivalent to V2.1
mg/ml cisplatin, which is the established solubility
of cisplatin at this temperature. Increasing the con-
centration of 2000PEG up to 40% increased the sol-
ubility of cisplatin at RT by V60%, reaching V3.3
mg/ml, as observed by NMR. The insoluble cisplatin
precipitated as a yellow solid at the bottom of the
NMR test tubes.
3.6.2. E¡ect of 2000PEG on the linewidth of the
cisplatin peak in 195Pt NMR
Table 4 shows the e¡ect of increasing the concen-
tration of 2000PEG on the linewidth of the cisplatin
peak. The experiment was carried out at room tem-
perature to isolate the e¡ect of the 2000PEG and ex-
clude the contribution of a rise in temperature. It was
found that as the 2000PEG concentration increased,
the linewidth decreased.
4. Discussion
In order to reach tumor sites in a therapeutically
signi¢cant way, liposomal formulations must have a
su⁄cient and stable drug load, as well as long circu-
lation time. The liposomes should be small enough
(V100 nm) so that they can extravasate into the
tumor tissue [15,16,24]. A size of V100 nm imposes
a limitation on the drug loading, especially when it is
passive. The solubility of the drug is limited, and the
drug has low a⁄nity to the lipid membrane. To im-
prove the drug-to-lipid ratio, drug loading was per-
formed at high temperatures (60^65‡C), at which the
drug solubility is V8 mg/ml (4-fold higher than at
room temperature). On completion of the prepara-
tion of loaded LUV, the temperature was lowered to
4‡C, a temperature at which the drug solubility is
limited to V1 mg/ml. This preparation, in which
the drug concentration exceeds its solubility by
8-fold, raised a question regarding the physical state
of the drug and its stability inside the liposomes dur-
ing storage at 4‡C. Another important question is
related to the drug-lipid interaction: if and how the
liposome formulation a¡ects the drug and, in turn,
how the drug a¡ects the liposomes. Through the ap-
plication of various NMR techniques, including
195Pt, 1H-15N-HSQC and 31P NMR, we were able
to gather information in an attempt to answer these
questions.
4.1. E¡ect of cisplatin on liposome lipids
31P NMR was used to verify the state of phospho-
lipids in vesicle membranes as well as to verify the
Table 4
195Pt NMR linewidths at half the height measured for 2 mg/ml
cisplatin in the presence of 2000PEG
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homogeneity of liposomal preparations with respect
to size distribution and number of lamellae
[22,25,26]. Comparison between the cisplatin-con-
taining LUV and the control, cisplatin-free LUV
shows that they di¡er, although both liposome prep-
arations have identical lipid concentration and sim-
ilar size distribution (see Table 2). This suggests
at least minor interactions between the cisplatin
and the phospholipid, as vX1=2 Pt-liposomes (4.2
ppm)6vX1=2 control (6.3 ppm). The linewidth data
are in good agreement with many previously re-
ported 31P measurements of 100^200 nm diameter
LUV (i.e., vX1=2W5 ppm for egg PC/DSPG, 85:15)
[26]. Such linewidths suggest lack of contamination
with MLV, while the shape of the peaks clearly
shows that there are no phospholipids in a hexagonal
type II state [26]. Factors such as the vesicle size, the
grafted PEG moiety or the presence of ethanol are
ruled out as an explanation for the di¡erence in vX1=2
since they are present and similar in both the cispla-
tin-free and the cisplatin-containing formulations.
Therefore, it is likely that a direct or indirect inter-
action between the drug and the phospholipids, as
well as the e¡ect on hydration due to the preferential
distribution of cisplatin in the PEG layer near the
phospholipid head group (see Section 4.3), are re-
sponsible for the di¡erences in vX1=2. Further experi-
ments are necessary in order to clarify the nature of
this interaction.
4.2. E¡ect of liposomal encapsulation on the chemical
stability of cisplatin
195Pt NMR spectroscopy provides information on
the oxidation state of the metal and on the nature of
the four ligands in platinum’s ¢rst coordination
sphere. This is due to the fact that the chemical shift
range of Pt complexes spans several thousand ppm
and that the chemical shift is sensitive to both the
oxidation state of the Pt (II and IV) and to the na-
ture of the atom which is bound to the Pt. 195Pt
NMR is considered one of the most powerful tools
for characterizing platinum complexes. The draw-
backs of platinum NMR stem from the low natural
abundance of the 195 isotope (33%) and from the
chemical shift anisotropy (CSA) relaxation pathway
of the Pt complexes. The quadrupole moment of the
14N ligand causes the peaks to broaden such that the
peak width at half-height (g1=2) for K2PtCl4 is V50
Hz, for Pt(NH3)2Cl2 it is V200 Hz; while for
Pt(NH3)4 it is V1150 Hz. The broadening of the
peaks masks any information about couplings to
the nitrogen ligands (and to the protons) and reduces
the signal-to-noise ratio of the spectrum. Moreover,
195Pt NMR spectroscopy cannot be used to study the
binding of Pt complexes to biopolymers since the
slow rotational correlation time will broaden the
peaks beyond detection.
While 195Pt NMR spectroscopy provides informa-
tion on the oxidation state of the Pt complex and on
the nature of atoms in the ¢rst coordination sphere,
it cannot distinguish between a water ligand, a car-
boxy ligand or a phosphate ligand, since they all
bind the Pt through an oxygen atom. 15N NMR
spectroscopy has been used in conjunction with
195Pt NMR spectroscopy to provide the missing in-
formation [23,27]. The 15N chemical shift and the
15N-195Pt coupling constants are sensitive to the li-
gand that is trans to the 15N [28]. The lack of 14N
causes the 195Pt resonance to be sharp, and the cou-
pling constants (195Pt-15N, 195Pt-1H) can be obtained.
While it is easy to prepare 15N-labeled cisplatin (cis-
Pt(15NH3)2Cl2), direct detection of the 15N nucleus is
di⁄cult due to its low sensitivity.
Inverse detection experiments circumvent the
above-mentioned problem by detecting the protons
that are coupled to 15N. This two-dimensional tech-
nique provides information about the chemical shifts
and coupling constants of the 15N, which depend on
the ligands in the ¢rst coordination sphere of the Pt,
and on its oxidation state. The main advantage of
using 15N-labeled cisplatin is the ability to apply het-
eronuclear single or multiple quantum coherence
(HSQC or HMQC) NMR techniques. HSQC and
HMQC are two-dimensional inverse detection meth-
ods that have the proton chemical shifts on one axis
and the 15N chemical shifts on the second axis.
HSQC and HMQC of 15N-labeled Pt complexes
have been used successfully to detect micromolar
concentrations of Pt complexes.
The initial formulations with the cisplatin included
the addition of a histidine bu¡er prior to encapsula-
tion in the liposomes. 1H-15N-HSQC NMR is sensi-
tive enough to detect even the slightest impurities in
the sample. This was the case with the histidine bu¡-
er that was used in the process of platinum encapsu-
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lation in the liposomes. It is known that some amino
acids, such as histidine and methionine, may react
with cisplatin [29]. These associations are irreversible,
thus making the drug unavailable and ine¡ective,
once bound. To avoid any inactivation of cisplatin
by histidine during the preparation of STEALTH
cisplatin, no histidine bu¡er was added until the en-
capsulation was completed, and any unencapsulated
drug was removed (see Section 3.3.3).
The incubation experiments we have carried out
suggest that there is no contact between the histidine
bu¡er and 15N-cisplatin, and that in STEALTH cis-
platin, the liposomes do not leak and are very stable.
That is, there is no cisplatin associated with the ex-
ternal face of the liposome membrane, and the lack
of leakage of the 15N-labeled cisplatin from the lipo-
somes is proven by the fact that peaks belonging to
cisplatin-histidine species are not observed.
4.3. Physical state of liposome-encapsulated
cisplatin
A very important parameter to be determined re-
garding the platinum encapsulated in the liposomes
is the drug-to-lipid ratio, and what fraction of the
liposomal drug is behaving like water-soluble cispla-
tin. In the case of cisplatin, it is expected that only
the soluble portion of the drug within the liposome
will be bioavailable to act upon cellular DNA; any
cisplatin precipitate may be considered as unavail-
able and ine¡ective. The comparative study we
have carried out indicated that, unlike atomic ab-
sorption spectroscopy, it was possible to use 195Pt
NMR measurements in order to selectively quantify
the soluble cisplatin (see Table 3) and thus obtain a
clear indication as to the physical states of the cis-
platin contained in the liposomes. Any platinum in
the solid state (i.e., in a crystalline state or as a pre-
cipitate or even in a suspension of very ¢ne particles)
would be undetected by 195Pt NMR, as lines will
broaden to such an extent that they would disappear
into the baseline.
The agreement between the 195Pt NMR and
atomic absorption data for STEALTH cisplatin in-
dicates that nearly all the cisplatin accounted for by
atomic absorption is also detected by 195Pt NMR,
and is therefore soluble in the intraliposomal aque-
ous phase. This suggests that at 4‡C or at room
temperature, the intraliposomal concentration is
higher than 1^2 mg/ml, which is the bulk solubility
limit at these temperatures. Further, the NMR mea-
surements indicate that the solubility of free cisplatin
in the bulk at 18‡C in the aqueous phase is limited to
V2 mg/ml, and is increased to at least 8 mg/ml upon
a rise in temperature to 60‡C. These results are in
good agreement with the visual precipitation studies
performed (Section 3.4.2). The NMR studies, when
combined with the solubility measurements and
AAS, led us to conclude that the encapsulated cis-
platin does not precipitate in the liposomes. This
result is in good agreement with extended X-ray ab-
sorption ¢ne structure (EXAFS) analysis performed
by Lasic et al. [30]. Since this ¢nding was surprising,
it was imperative to try to determine the factors in
the preparation that yielded a solubility of cisplatin
that is normally obtained only at 65‡C.
Ethanol is present during the ¢rst stages of lipo-
some formulation, and therefore its e¡ect on the sol-
ubility of cisplatin had to be evaluated. The solubility
studies performed (Section 3.4.2) led us to conclude
that the presence of 20% ethanol did not improve the
solubility of cisplatin and is not responsible for the
higher than expected drug-to-lipid ratio.
Since ethanol had no e¡ect as an enhancer of cis-
platin solubility, other parameters were explored.
The contribution of the grafted PEG was studied,
since PEG is known to a¡ect solubility in both or-
ganic and aqueous media [31^34]. In STEALTH cis-
platin, the liposomes consist of 5 mole% 2000PEG-
DSPE. This high PEG concentration grafted in prox-
imity to the inner lea£et of the LUV, being in the
transition between brush and mushroom con¢gura-
tions, and highly hydrated [35], can contribute to the
elevated solubility of cisplatin. Therefore, we have
tested the e¡ect of 2000PEG on the solubility of cis-
platin by 195Pt NMR and by visual assessment stud-
ies. As the concentration of PEG in the solution is
increased, the amount of bound water increases ac-
cordingly, and the amount of unbound water is de-
creased. At 40% PEG, most of the water is bound to
the PEG (as hydration water [35]). The fact that the
solubility of cisplatin increases by some 64% (from
2.1 to 3.3 mg/ml) indicates that cisplatin is soluble in
the PEG hydration water and that its solubility in
this water is greater than its solubility in bulk water.
Therefore, in STEALTH cisplatin, the elevated sol-
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ubility of cisplatin suggests that at least part of the
cisplatin is found in the bound water layer. In addi-
tion, the water structure probably contributes to the
correlation time, tc, as the linewidth (vX1=2) is re-
duced with the increase in PEG from V759 Hz at
5% PEG toV284 Hz at 40% PEG (see Table 4). The
nature of this contribution has yet to be determined,
since it would be expected that the opposite would
occur. Since elevated concentrations of PEG increase
the viscosity of the sample, it would be expected that
lines would be broader, whereas the reported results
indicate reduced linewidths.
The intraliposomal water includes bulk water and
hydration water. For a lipid composition with ¢xed
levels of 2000PEG-DSPE, the liposome’s shape and
size will determine the ratio between bulk and sur-
face hydration water in the intraliposomal aqueous
phase. If a similar shape is assumed, then size alone
will be the determining factor. This can be expressed
as an area/volume ratio that increases as the lipo-
some size decreases. That is, the smaller the lipo-
somes, the larger is the relative fraction of water
associated with the PEG moiety. Therefore, the
smaller the liposomes, the higher is the relative sol-
ubility of cisplatin in the intraliposomal aqueous
phase. Also, the smaller the liposome, the higher is
the fraction of cisplatin in the PEG layer. Therefore,
vX1=2 of the liposomal cisplatin should be shorter, as
is demonstrated in Table 1. The contribution of the
altered water activity with cisplatin is suggested by
the HSQC data obtained: (i) The only di¡erence
between the spectrum of cis-Pt(15NH3)2Cl2 passively
encapsulated in the aqueous phase of the liposomes
and that of the drug in the bulk medium is that the
distance between the satellite peaks is somewhat
smaller than in the former. (ii) In addition, no peaks
attributed to the aqua species are observed. The 31P
NMR results described in Section 3.2 and the lack of
peaks attributed to the aqua species support the ex-
planation of ‘low’ average water activity inside the
liposomes, compared to the activity of bulk water.
This is not surprising, since the internal volume of
V100 nm liposomes is small, and the PEGylated
lipid, which binds V180 mol water/mol 2000PEG
moiety [35], reduces the amount of unbound water
inside the liposome. The increasing size of the lipo-
some is accompanied by a net decrease in the ratio
between the volume of the PEG layer and the inter-
nal aqueous volume, as expected from the e¡ect of
LUV size on the area/volume ratio.
Other parameters which may explain the improved
cisplatin solubility in the intraliposomal aqueous
phase of STEALTH cisplatin include the increase
of liposome size by swelling and/or shape changes
after the liposome preparation was cooled down.
The liposome internal aqueous volume may also in-
crease during the cooling process due to a change in
liposome shape (i.e., from non-spherical to spheri-
cal). Overall, when the liposome size is increased,
the fraction of cisplatin present in the intraliposomal
unbound water is increased. The observed e¡ect of
2000PEG on the linewidth of the cisplatin peak (Table
4) is in agreement with the inverse correlation be-
tween the LUV size and the width of the cisplatin
peak observed (Table 1). This phenomenon repeated
itself at both 37‡C and at 60‡C, yet was somewhat
more obvious at the higher temperature (Table 1).
This suggests a direct or indirect interaction between
the PEG moiety of the lipopolymer and cisplatin
(probably through water). As the liposome size in-
creases, the amount of unbound water within in-
creases, as there is an increase in the volume per
area. This argument further strengthens our sugges-
tion that cisplatin is also found in the bound water
within the liposome, although this by itself accounts
only for part of the improved solubility, leading to
the higher than expected concentration of cisplatin
found in the liposomes. It is highly likely that encap-
sulation in the small internal volume of the lipo-
somes leads to the formation of a special microenvi-
ronment which further contributes to the very high
drug loading and the higher than expected drug-to-
lipid ratio.
5. Conclusions
Our studies on STEALTH cisplatin show that
NMR is a powerful tool in the characterization of
drug-lipid interactions, the physical state of the drug
inside the liposomes, the chemical stability of the
drug, and the barrier properties of the liposomes.
Several conclusions stem from these NMR studies.
b As long as histidine is added after the drug encap-
sulation, cisplatin remains intact during the load-
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ing process. Encapsulated cisplatin resembles, with
minor di¡erences, the parent compound dissolved
in the aqueous phase.
b All the cisplatin present in the liposomes behaves
like a water-soluble drug, and there is no indica-
tion of any insoluble drug. That is, the drug within
the liposomes does not precipitate or crystallize.
b Drug-membrane interactions exist but are mini-
mal.
b Drug encapsulated in the liposomes is very stable:
no e¥ux of drug or in£ux of medium components
was observed.
b Improved cisplatin solubility over bulk solubility is
explained by the contribution of the membrane-
grafted 2000PEG and possibly by the small size of
the internal aqueous compartment.
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